Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer

Authors

Kadoaki Ohashi (ORCID: https://orcid.org/0000-0002-5180-3933)
Hiroki Izumi (ORCID: https://orcid.org/0000-0002-9566-4859)
Hiroko Akamatsu (ORCID: https://orcid.org/0000-0001-8086-8974)
Ji‐Youn Han (ORCID: https://orcid.org/0000-0001-5033-0006)
Myung‐Ju Ahn (ORCID: https://orcid.org/0000-0002-5376-5109)
Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
Chi‐Lu Chiang (ORCID: https://orcid.org/0000-0003-1093-0669)
Ali Hamidi (ORCID: https://orcid.org/0000-0002-1096-5119)
Kang Xu (ORCID: https://orcid.org/0000-0002-6946-8635)
Jong-Seok Lee (ORCID: https://orcid.org/0000-0003-3733-3573)
Shuang Huang
Sujoy Mukherjee (ORCID: https://orcid.org/0000-0001-9783-7664)

Institutions

Amgen (United States) (US)
Wakayama Medical University (JP)
Yonsei University (KR)
Samsung Medical Center (KR)
Taipei Veterans General Hospital (TW)
Seoul National University Bundang Hospital (KR)
National Cancer Center (US)
Okayama University Hospital (JP)
National Cancer Center Hospital East (JP)
Adaptations Glassware Cooperative (US)

Publication Details

Journal: Oncology and Therapy
Published: 2025-09-04
DOI: https://doi.org/10.1007/s40487-025-00372-0
Citations: 1
Primary Topic: Lung Cancer Research Studies
Type: article
Field-Weighted Citation Impact: 1.05

Funders

Amgen

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer

Kadoaki Ohashi, Hiroki Izumi, Hiroko Akamatsu, Ji‐Youn Han et al.

Sep 4, 2025

1 citations

Oncology and Therapy

Lung Cancer Research Studies

1.05

article

Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer

Kadoaki Ohashi, Hiroki Izumi, Hiroko Akamatsu, Ji‐Youn Han, Myung‐Ju Ahn, Byoung Chul Cho, Chi‐Lu Chiang, Ali Hamidi, Kang Xu, Jong-Seok Lee, Shuang Huang, Sujoy Mukherjee

September 4, 2025article en

1 citations

Abstract

No abstract available for this paper.

Oncology and TherapyVol. 13(4)

Amgen (United States) (US), Wakayama Medical University (JP), Yonsei University (KR), Samsung Medical Center (KR), Taipei Veterans General Hospital (TW), Seoul National University Bundang Hospital (KR), National Cancer Center (US), Okayama University Hospital (JP), National Cancer Center Hospital East (JP), Adaptations Glassware Cooperative (US)

Amgen

Openalex Percentile: Top 18%

Lung Cancer Research Studies

1.05

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer — Kadoaki Ohashi, Hiroki Izumi, et al. · Oncology and Therapy (2025) | TGRS Research Map | TGRS